In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the ...

Researchers in Purdue University's College of Pharmacy have developed and validated a new series of small-molecule inhibitors ...

InxMed Co., Ltd ('InxMed'), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting ...

Preclinical manuscript that characterizes the mechanism of action, broad antitumor efficacy, and immune-activating properties ...

SSRIs enhance CD8 T cell antitumor activity by inhibiting SERT, an immune checkpoint in tumors, suggesting potential repurposing for cancer immunotherapy. High intratumoral SERT levels correlate with ...

A HER3-DXd and olaparib combination enhanced DNA damage, apoptosis, and antitumor immune activity in preclinical NSCLC models.

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), providing a safe and effective oral targeted ...

Zhong-Yin Zhang leads a team that has developed and validated a novel series of small-molecule inhibitors that promote ...